Table 2.

Clinical characteristics of the patients diagnosed as having SARS-CoV-2 infection

SARS-CoV-2 infection % (range) Total (N=56), n/N 
No 49 53/109 
Yes 51 56/109 
COVID-19 severity   
Asymptomatic 16.1 9/56 
Mild 16.1 9/56 
Moderate 35.7 20/56 
Severe 19.6 20/56 
Critical 12.5 7/56 
COVID-19 treatment   
No treatment 30.4 17/56 
Treatment 69.6 39/56 
COVID-19–specific treatment   
Remdesivir 76.9 30/39 
Sotrovimab 51.3 20/39 
Tocilizumab 25.6 10/39 
Convalescent plasma 33.3 13/39 
Paxlovid 28.2 11/39 
First SARS-CoV-2 infection, median days for negativization (range) 36.0 (1.0-386.0)  
Second SARS-CoV-2 infection, median days for negativization (range) 47.5 (5.0-180.0)  
SARS-CoV-2 infection during treatment   
No 51.8 29/56 
Yes 48.2 27/56 
SARS-CoV-2 infection after treatment   
No 48.2 27/56 
Yes 51.8 29/56 
BsAbs treatment interrupted   
No 22.2 6/27 
Yes 77.7 21/27 
BsAbs treatment discontinued   
No 81.5 22/27 
Yes 18.5 5/27 
SARS-CoV-2 infection % (range) Total (N=56), n/N 
No 49 53/109 
Yes 51 56/109 
COVID-19 severity   
Asymptomatic 16.1 9/56 
Mild 16.1 9/56 
Moderate 35.7 20/56 
Severe 19.6 20/56 
Critical 12.5 7/56 
COVID-19 treatment   
No treatment 30.4 17/56 
Treatment 69.6 39/56 
COVID-19–specific treatment   
Remdesivir 76.9 30/39 
Sotrovimab 51.3 20/39 
Tocilizumab 25.6 10/39 
Convalescent plasma 33.3 13/39 
Paxlovid 28.2 11/39 
First SARS-CoV-2 infection, median days for negativization (range) 36.0 (1.0-386.0)  
Second SARS-CoV-2 infection, median days for negativization (range) 47.5 (5.0-180.0)  
SARS-CoV-2 infection during treatment   
No 51.8 29/56 
Yes 48.2 27/56 
SARS-CoV-2 infection after treatment   
No 48.2 27/56 
Yes 51.8 29/56 
BsAbs treatment interrupted   
No 22.2 6/27 
Yes 77.7 21/27 
BsAbs treatment discontinued   
No 81.5 22/27 
Yes 18.5 5/27 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal